Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: Single-center experience

Clinical Neurology and Neurosurgery

Volumn 111, Issue 8, 2009, Pages 679-682

  Jeon, Hyung Jun ^a   Kong, Doo Sik ^a   Park, Kwon Byong ^a   Lee, Jung Il ^a   Park, Kwan ^a   Kim, Jong Hyun ^a   Kim, Sung Tae ^a   Lim, Do Hun ^a   Kim, Won Seok ^a   Nam, Do Hyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adjuvant; Concomitant chemoradiation; Glioblastoma; Pseudoprogression; Temozolomide; Toxicity

Indexed keywords

ANTIEMETIC AGENT; COTRIMOXAZOLE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE PERIOD; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; KOREA; MALE; MIDDLE AGED; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68849132197     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2009.06.013     Document Type: Article

References (16)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Jefferies S., Burton K., Jones P., and Burnet N. Interpretation of early imaging after concurrent radiotherapy and temozolomide for glioblastoma. Clin Oncol (R Coll Radiol) 19 (2007) S33
3. Cao Y., Sundgren P.C., Tsien C.I., Chenevert T.T., and Junck L. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 24 (2006) 1228-1235
4. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
5. Taphoorn M.J.B., Stupp R., Coens C., Osoba D., Kortmann R., van den Bent M.J., et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6 (2005) 937-944
6. Rosenthal M.A., Drummond K.J., Dally M., Murphy M., Cher L., Ashley D., et al. Management of glioma in Victoria (1998-2000): retrospective cohort study. Med J Aust 184 (2006) 270-273
7. Laws E.R., Parney I.F., Huang W., Anderson F., Morris A.M., Asher A., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Gliomas Outcome Project. J Neurosurg 99 (2003) 467-473
8. Stupp R., Hegi M.E., van den Bent M.J., Mason W.P., Weller M., Mirimanoff R.O., et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11 (2006) 165-180
9. Chamberlain M.C., Glantz M.J., Chalmers L., Van Horn A., and Sloan A.E. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82 (2007) 81-83
10. de Wit M.C., de Bruin H.G., Eijkenboom W., Sillevis Smitt P.A., and van den Bent M.J. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63 (2004) 535-537
11. Schlemmer H.P., Bachert P., Henze M., Buslei R., Herfarth K.K., Debus J., et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 44 (2002) 216-222
12. Simpson J.R., Hortan J., Scott C., Curran W.J., Rubin P., Fischbach J., et al. Influence of location and extent of surgical resection on survival of patients of glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26 (1993) 239-244
13. Buckner J.C. Factors influencing survival in high-grade gliomas. Semin Oncol 30 Suppl 19 (2003) 10-14
14. Stupp R., Ostermann S., and Leyvrav S. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol 20 59a (2001) [abstract 232]
15. Stupp R., Dietrich P.Y., Kraljevic S.O., Pica A., Maillard I., Maeder P., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 (2002) 1375-1382
16. Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10 6 (2004) 1871-1874 15